STK17A

Across TCGA pan-cancer cohorts, STK17A mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated STK17A data layer compared with 18 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher STK17A mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated STK17A expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

PDAC, CCRCC, and HNSC are the cancer types where STK17A mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Tertile	All	0.365	0.799	.001	43	view →
CCRCC	DFS	Median	III,IV	0.370	0.786	.001	15	view →
HNSC	OS	Median	III,IV	1.000	0.449	.023	10	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	4	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

STK17A–PDAC (DFS)

Open the PDAC breakdown →